VISIT-HARDANGERFJORD
21.6.2024 13:11:35 CEST | Business Wire | Press release
Trolltunga, Norway's most spectacular rock formation, has become a dream wedding destination. This year, a record number of couples exchanged vows on the longest day of the year, with ceremonies lasting until midnight on the Instagram hotspot.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240621968668/en/
"We came across a post on social media, and it feels surreal to finally be standing here on Trolltunga. We have been looking forward to this for a long time. It is incredible", explains Daniele Arcuri & Lavinia Paretti. (Photo: Business Wire)
For the first time, wedding ceremonies on Trolltunga lasted until midnight to accommodate a record number of couples. Conducting the ceremonies on the longest day of the year – the day with the most daylight – provided a unique and unforgettable wedding backdrop.
"We wanted to do something special for our wedding, and now we are standing in the most beautiful nature we have ever seen. We are almost speechless. This was a truly fantastic experience", says Daniele Arcuri & Lavinia Paretti from Italy.
An International Dream
Mayor Roald Aga Haug married twenty couples from 11 countries, including Norway, Scotland, Germany, Romania, Italy, Poland, Costa Rica, Latvia, Lithuania, Sweden, and Denmark. Multiple couples describe it as a "dream to be married in the Norwegian nature" and feel "blessed to be allowed to do this."
"We loved it. This was exactly what we wanted and came to Norway & Trolltunga for", says Federica Migliori and Luka Landucci, who also travelled from Italy.
A Growing Trend in Fairytale Landscape
Interest in nature weddings in Norway has increased significantly in recent years. When the possibility was first introduced, three couples got married on Trolltunga. The number has now grown to 20 couples for several reasons. Record-high temperatures in Europe have sparked massive interest in the Norwegian fjords. Never before have there been so many tourists in the Hardangerfjord region – just outside Bergen.
The wedding day started with a 10-kilometer hike to Trolltunga. Equipment and wedding dresses were transported by helicopter, and several tents were set up for the couples to change before the ceremonies. Local musicians played captivating music to set the right mood during the ceremonies.
A Revitalized Region
Although weddings do not generate significant income, the increased interest in vacationing in Norway and Hardanger has led to million-dollar regional investments. The area is now flourishing with new activities and attractions every year. Hardanger, including Trolltunga, has become one of the most popular destinations in Norway.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240621968668/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom